Komori
Japan Tissue Engineering (7774) · InitiativeAchieved

Covering an Accumulated Deficit and Increasing Capital Policy Flexibility through Reductions in Stated Capital and Capital Reserves

First written in FY2016. 2 of 4 entries say "Achieved", first in FY2017-Q1. Latest entry: FY2026-H1.

4entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAchievedFY2017-Q1 – FY2026-H12016: 220162017: 020172018: 020182019: 020192020: 020202021: 020212022: 020222023: 020232024: 020242025: 22025
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 298 companies write about · 1 as a headwind · 297 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 300 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AchievedAnnual report

    「Based on a resolution of the 27th Annual General Meeting of Shareholders held on 19 June 2025, the reduction of capital took effect on 1 August 2025. During the interim accounting period, stated capital and capital reserve each decreased by ¥961.089 million, while other capital surplus increased by ¥1,922.179 million. The increased other capital surplus of ¥1,922.179 million was applied to cover the deficit by transferring it to retained earnings carried forward.」

    The planned reductions in stated capital and capital reserve and the application of funds to cover the deficit took effect on 1 August 2025 and were completed.
  2. FY2025AdvancedAnnual report

    「The company decided to reduce the amounts of its stated capital and capital reserve pursuant to Articles 447(1) and 448(1) of the Companies Act and dispose of surplus pursuant to Article 452, in order to eliminate the deficit in retained earnings currently arising, strengthen its financial position, create the conditions for future shareholder returns such as dividend payments and share repurchases, and ensure flexibility and agility in its future capital policy.」

    At the General Meeting of Shareholders held on 19 June 2025, a plan was approved to reduce stated capital and capital reserve by ¥961,089,987 each and transfer the entire ¥1,922,179,974 in other capital surplus to cover the deficit. The effective date is scheduled for 1 August 2025.
  3. FY2017-Q1AchievedAnnual report

    「At the 18th Annual General Meeting of Shareholders held on 23 June 2016, the company received approval for reductions in stated capital and capital reserve and the disposition of surplus. The measures took effect on 1 August 2016.」

    The reduction of stated capital and capital reserve by ¥6,574,636,705 each and the transfer of ¥13,149,273,410 in other capital surplus to cover the deficit took effect, completing the capital reduction and disposition of surplus.
  4. FY2016First statedAnnual report

    「The company decided to reduce the amounts of its stated capital and capital reserve pursuant to Articles 447(1) and 448(1) of the Companies Act and dispose of surplus pursuant to Article 452, in order to eliminate the deficit in retained earnings currently arising, strengthen its financial position, create the conditions for future shareholder returns such as dividend payments and share repurchases, and ensure flexibility and agility in its future capital policy.」

    The company disclosed a plan, scheduled for 1 August 2016, to reduce stated capital and capital reserve by ¥6,574,636,705 each and apply ¥13,149,273,410 to cover the deficit.
Moved together

"Wider adoption of the autologous cultured cartilage JACC procedure and expansion of certified facilities authorized to perform it" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Wider adoption of the autologous cultured cartilage JACC procedure and expansion of certified facilities authorized to perform it2×
  3. 2Promoting the adoption of alternatives to animal testing using cultured human tissues for research2×
  4. 3Strengthening the sales structure through sales and educational activities for medical institutions and the use of distributors2×
  5. 4Entry into the development, manufacture and sale of CAR-T cell therapies2×
  6. 5Expansion into dermatology through melanocyte-containing autologous cultured epidermis ACE022×
  7. 6Conducting clinical trials for autologous cultured corneal epithelium and obtaining early approval2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Japan Tissue Engineering's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.